NEW YORK, Oct. 22 - Functional genomics company Galapagos Genomics and Procter & Gamble Pharmaceuticals have entered into a gene target-discovery and -validation research collaboration, the firms said on Monday.  

Terms of the two-year agreement call for Galapagos, of Mechelen, Belgium, to supply P&GP with adenoviral vectors that contain human genes selected by P&GP researchers. Galapagos will construct the recombinant adenoviruses using its PhenoSelect expression platform, the company said in a statement. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.